These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 16123497)
21. Does insulin and not reduced blood glucose levels decrease postoperative infections? Stoecklein K; Eekhof EW; Loer SA; Boer C Eur J Anaesthesiol; 2012 Aug; 29(8):401-2. PubMed ID: 22513482 [No Abstract] [Full Text] [Related]
22. Approaches to treatment 1: How is type 2 diabetes actually treated? Bloomgarden ZT J Diabetes; 2015 Nov; 7(6):747-8. PubMed ID: 26211568 [No Abstract] [Full Text] [Related]
23. Jentadueto XR for type 2 diabetes. Med Lett Drugs Ther; 2016 Aug; 58(1500):98-100. PubMed ID: 27466749 [No Abstract] [Full Text] [Related]
24. Rationale and design of the AdRem study: evaluating the effects of blood pressure lowering and intensive glucose control on vascular retinal disorders in patients with type 2 diabetes mellitus. Chaturvedi N; Bilous R; Sjolie AK; Klein R; Contemp Clin Trials; 2007 Nov; 28(6):780. PubMed ID: 17643353 [No Abstract] [Full Text] [Related]
25. Homocysteinemia is not changed by 3-day insulin-induced normoglycemia in type 2 diabetic subjects. Beauvieux MC; Rigalleau V; Perlemoine C; Baillet L; Gin H Diabetes Care; 2003 Aug; 26(8):2475-6. PubMed ID: 12882887 [No Abstract] [Full Text] [Related]
26. Extent of glycemic control in type 2 diabetes mellitus: close, but no cigar. Lerch C; Richter B Nutr Metab Cardiovasc Dis; 2009 Nov; 19(9):593-5. PubMed ID: 19833492 [No Abstract] [Full Text] [Related]
27. Optimizing glycemic control with insulin glargine. Williams JB Diabetes Technol Ther; 2003; 5(3):471-3. PubMed ID: 12828834 [No Abstract] [Full Text] [Related]
28. Sodium-glucose co-transporter inhibition in the treatment of diabetes: sweetening the pot. Alvarez CA; Neeland IJ; McGuire DK Diab Vasc Dis Res; 2015 Mar; 12(2):74-7. PubMed ID: 25690133 [No Abstract] [Full Text] [Related]
32. Editorial: Natural Compounds and Their Derivatives as a Source of Promising Drugs for Diabetes and Insulin Resistance. Mena Barreto Silva FR; Silva Frederico MJ Curr Drug Targets; 2017; 18(6):618. PubMed ID: 28831919 [No Abstract] [Full Text] [Related]
33. [The extra-glycemic effects of liraglutide: focus on cardiometabolic markers]. Giglio RV; Patti AM; Nikolic D; Castellino G; Noto M; Parrino A; Montalto G; Rizzo M G Ital Cardiol (Rome); 2016 Apr; 17(4):253-8. PubMed ID: 27093208 [TBL] [Abstract][Full Text] [Related]
34. Starting insulin therapy in type 2 diabetes: lesson 2. McCall AL Curr Diab Rep; 2005 Oct; 5(5):326-8. PubMed ID: 16188165 [No Abstract] [Full Text] [Related]
35. Pharmacological regulation of blood glucose levels in non-insulin-dependent diabetes mellitus. Bressler R; Johnson DG Arch Intern Med; 1997 Apr; 157(8):836-48. PubMed ID: 9129543 [TBL] [Abstract][Full Text] [Related]
36. Chronic Kidney Disease in Type 2 Diabetes: Optimizing Glucose-Lowering Therapy. Bakris G J Fam Pract; 2019 Oct; 68(8):S1-S6. PubMed ID: 31697796 [No Abstract] [Full Text] [Related]
37. Should diabetic patients treated long-term with sulfonylureas be switched to nateglinide? Sevinc A Arch Intern Med; 2003 Jul; 163(14):1741. PubMed ID: 12885691 [No Abstract] [Full Text] [Related]
38. Novel approaches to treating type 2 diabetes. Nauck MA Diabetologia; 2016 Feb; 59(2):227-8. PubMed ID: 26637430 [No Abstract] [Full Text] [Related]
39. Glucose-targeted therapy for subjects with type 2 diabetes mellitus: primum non nocere. Maggi D; Bordone C; Briatore L; Cheli V; Fontana L; Mazzucchelli C; Montecucco F; Adami G; Cordera R Eur J Clin Invest; 2017 Oct; 47(10):691-693. PubMed ID: 28746976 [No Abstract] [Full Text] [Related]